guardant | Home - GuardantHealth

Keyword	CPC	PCC	Volume	Score	Length of keyword
guardant	0.56	0.6	1732	67	8

Keyword	CPC	PCC	Volume	Score
guardant health	1.81	0.8	6331	95
guardant360	1.4	0.1	6363	59
guardant	0.97	0.7	4451	17
guardant health careers	1.67	0.5	6442	53
guardant health stock	1.92	0.1	5881	11
guardant reveal	0.79	0.8	547	3
guardant portal	0.74	0.9	7617	99
guardant login	0.92	0.5	4025	5
guardant 360 cdx	0.29	0.7	7321	76
guardant health login	0.62	0.7	4982	39
guardant health portal	1.26	0.7	66	27
guardant health stock price	1.86	0.3	9999	81
guardant360 login	0.48	0.8	5458	54
guardant drivers	1.06	0.4	9593	6
guardant 360 portal	1.8	0.7	1215	76
guardant code usb driver	0.32	0.5	2606	46
guardant mrd	1.33	0.7	5766	13
guardant dongle not found pcmflash	0.2	0.3	1830	49
guardant health news	0.74	0.5	7478	99
guardant health address	1.3	1	6250	40
guardant health shield	0.45	0.4	631	18
guardant health japan	0.21	0.4	4847	92
guardant health investor relations	0.48	0.7	1560	12
guardant health logo	1.07	0.9	936	63
guardant health stock forecast	0.65	0.9	4595	85
guardant health share price	1.19	0.4	2773	42
guardant health amea	1.88	0.8	1295	81
guardant health palo alto	1.78	0.8	9213	77
guardant health redwood city ca	1.15	0.8	4435	21
guardant health competitors	0.62	1	919	69
guardant health inc	1.32	0.2	6536	56
what is guardant health	1.45	1	5718	5
yahoo finance guardant health	0.16	0.3	2140	8

Search Results related to guardant on Search Engine

Home - GuardantHealth
guardanthealth.com

https://guardanthealth.com/

WEBGuardant Health is a leading precision medicine company focused on transforming patient care and conquering cancer with data.

DA: 86 PA: 83 MOZ Rank: 82

Tests for Cancer Screening - GuardantHealth
guardanthealth.com

https://guardanthealth.com/products/tests-for-cancer-screening/

WEBScreening to find cancer early, when it’s most treatable. For asymptomatic adults at average risk of cancer, our blood test aims to ensure that all individuals eligible for cancer screening are screened.

DA: 45 PA: 53 MOZ Rank: 47

FDA Advisory Panel Review of Guardant Health’s Shield™ Blood …
yahoo.com

https://finance.yahoo.com/news/fda-advisory-panel-review-guardant-125200837.html

WEB1 day ago · PALO ALTO, Calif., April 22, 2024--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced the Molecular and Clinical Genetics Panel of the U.S. Food and Drug ...

DA: 59 PA: 29 MOZ Rank: 39

Our story - GuardantHealth
guardanthealth.com

https://guardanthealth.com/about/our-story/

WEBWe are dedicated to helping patients at all stages of cancer live longer and healthier lives through the power of blood tests and the data they unlock— from informing better treatment in patients with advanced cancer, to new ways of monitoring recurrence in cancer survivors, and screening to find cancer at its earliest and most treatable ...

DA: 26 PA: 29 MOZ Rank: 2

Tests for Patients with Advanced Cancer - GuardantHealth
guardanthealth.com

https://guardanthealth.com/products/tests-for-patients-with-advanced-cancer/

WEBThe first FDA-approved blood test for complete genomic testing. Our Guardant360 ® CDx test is FDA-approved for complete genomic testing across all solid cancers, providing doctors guideline-complete genomic results in 7 days from a simple blood draw to inform treatment decisions.

DA: 47 PA: 45 MOZ Rank: 14

Guardant Health - Wikipedia
wikipedia.org

https://en.wikipedia.org/wiki/Guardant_Health

WEBThe American biotechnology company Guardant Health, which produces liquid biopsy tests to detect cancer from mutations and other modifications in blood samples, [1] was co-founded by Helmy Eltoukhy and AmirAli Talasaz during 2012–2013. [2] [3] According to John Dorfman of the Pittsburgh Tribune-Review, Talasaz and Eltoukhy discovered a ...

DA: 12 PA: 14 MOZ Rank: 88

Guardant360® CDx: Fastest FDA-Approved Liquid CGP Panel
guardantcomplete.com

https://www.guardantcomplete.com/products/guardant360-cdx/

WEBGuardant360® CDx is the fastest FDA-approved CGP panel for all advanced solid tumors including lung, breast, and colorectal cancers. Results in less than 7 days.

DA: 63 PA: 24 MOZ Rank: 89

Guardant Health, Inc. - Guardant Health receives FDA approval …
guardanthealth.com

https://investors.guardanthealth.com/press-releases/press-releases/2023/Guardant-Health-receives-FDA-approval-for-Guardant360-CDx-as-companion-diagnostic-for-Menarini-Groups-ORSERDU-for-treatment-of-patients-with-ESR1-mutations-in-ER-HER2--advanced-or-metastatic-breast-cancer/default.aspx

WEBJan 30, 2023 · Guardant Health receives FDA approval for Guardant360® CDx as companion diagnostic for Menarini Group’s ORSERDU™ for treatment of patients with ESR1 mutations in ER+, HER2- advanced or metastatic breast cancer. January 30, 2023. ESR1 mutations, a known driver of resistance to standard endocrine therapy, are …

DA: 74 PA: 63 MOZ Rank: 21

For Patients - GuardantHealth
guardanthealth.com

https://guardanthealth.com/precision-oncology/for-patients/

WEBOur Guardant Access program helps patients navigate insurance eligibility, manage claims appeals, answer billing questions, and determine financial assistance eligibility for our tests. To learn more about how Guardant Access may be able to help you, please contact our Client Services Team: For Oncology Support:

DA: 97 PA: 60 MOZ Rank: 85

For Healthcare Providers - GuardantHealth
guardanthealth.com

https://guardanthealth.com/precision-oncology/for-healthcare-providers/

WEBAPPROACH. For healthcare providers. The latest advances in precision oncology are enabling important strides forward in the diagnosis, treatment, and management of cancer – across all stages of the disease. Screening Early-stage cancer Advanced cancer. How a simple blood draw can help healthcare providers increase screening compliance.

DA: 76 PA: 18 MOZ Rank: 65